NO2222861T3 - - Google Patents

Info

Publication number
NO2222861T3
NO2222861T3 NO08859393A NO08859393A NO2222861T3 NO 2222861 T3 NO2222861 T3 NO 2222861T3 NO 08859393 A NO08859393 A NO 08859393A NO 08859393 A NO08859393 A NO 08859393A NO 2222861 T3 NO2222861 T3 NO 2222861T3
Authority
NO
Norway
Application number
NO08859393A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2222861T3 publication Critical patent/NO2222861T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/24Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Artificial Filaments (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO08859393A 2007-12-11 2008-12-11 NO2222861T3 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US711807P 2007-12-11 2007-12-11
PCT/US2008/086409 WO2009076524A2 (en) 2007-12-11 2008-12-11 Polypurine tract modified retroviral vectors

Publications (1)

Publication Number Publication Date
NO2222861T3 true NO2222861T3 (sr) 2018-05-05

Family

ID=40756119

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08859393A NO2222861T3 (sr) 2007-12-11 2008-12-11

Country Status (16)

Country Link
US (2) US9796987B2 (sr)
EP (2) EP2222861B1 (sr)
JP (2) JP5749014B2 (sr)
CY (1) CY1119905T1 (sr)
DK (1) DK2222861T3 (sr)
ES (1) ES2664988T3 (sr)
HR (1) HRP20180184T1 (sr)
HU (1) HUE036103T2 (sr)
LT (1) LT2222861T (sr)
NO (1) NO2222861T3 (sr)
PL (1) PL2222861T3 (sr)
PT (1) PT2222861T (sr)
RS (1) RS56844B1 (sr)
SI (1) SI2222861T1 (sr)
TR (1) TR201802323T4 (sr)
WO (1) WO2009076524A2 (sr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
EP2526774A3 (en) 2006-07-21 2013-03-06 California Institute of Technology Targeted gene delivery for dendritic cell vaccination
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
SI2770061T1 (sl) * 2009-07-24 2019-02-28 Immune Design Corp. Neintegrirani lentiviralni vektorji
JP2014510721A (ja) 2011-02-15 2014-05-01 イミューン デザイン コーポレイション ベクターワクチンによる免疫原特異的免疫応答を強化するための方法
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
EP3542816A1 (en) 2014-02-14 2019-09-25 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
KR101607282B1 (ko) 2014-12-18 2016-03-29 충남대학교산학협력단 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2017066570A1 (en) * 2015-10-15 2017-04-20 The University Of North Carolina At Chapel Hill Methods and compositions for integration-defective lentiviral vectors
WO2017068419A2 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
AU2016354102B2 (en) 2015-11-09 2022-05-12 Immune Design Corp. A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
MX2018005467A (es) 2015-11-09 2018-12-11 Immune Design Corp Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas.
JP2019509275A (ja) 2016-02-23 2019-04-04 イミューン デザイン コーポレイション マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム
BR112018070934A2 (pt) 2016-04-15 2019-02-26 Alpine Immune Sciences, Inc. proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Immunomodulatory proteins that are variants of CD80 and their uses
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
CN109804089A (zh) 2016-07-29 2019-05-24 朱诺治疗学股份有限公司 用于评估复制型病毒存在或不存在的方法
MA46998A (fr) 2016-12-05 2019-10-09 Juno Therapeutics Inc Production de cellules modifiées pour une thérapie cellulaire adoptive
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
AU2018235835A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
CN110831963A (zh) 2017-03-16 2020-02-21 高山免疫科学股份有限公司 Pd-l1变体免疫调节蛋白及其用途
CA3070573A1 (en) 2017-07-29 2019-02-07 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
BR112020001605A2 (pt) 2017-08-09 2020-08-11 Juno Therapeutics Inc métodos para produzir composições de células geneticamente modificadas e composições relacionadas
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法
EP3704230A1 (en) 2017-11-01 2020-09-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
CA3080509A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for producing a t cell composition
CN112041430A (zh) 2017-12-08 2020-12-04 朱诺治疗学股份有限公司 用于培养细胞的无血清培养基配制品及其使用方法
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
EP3746569A1 (en) 2018-01-31 2020-12-09 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
AU2019345151A1 (en) 2018-09-19 2021-04-29 Alpine Immune Sciences, Inc. Methods and uses of variant CD80 fusion proteins and related constructs
BR112021008289A2 (pt) 2018-11-01 2021-10-26 Juno Therapeutics, Inc. Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b
CN113271963A (zh) 2018-11-16 2021-08-17 朱诺治疗学股份有限公司 给予工程化t细胞以治疗b细胞恶性肿瘤的方法
WO2020113188A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
EP3887394A2 (en) 2018-11-30 2021-10-06 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
SG11202105502RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
KR20220035032A (ko) 2019-04-17 2022-03-21 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도
US20220228101A1 (en) 2019-06-07 2022-07-21 Juno Therapeutics, Inc. Automated t cell culture
WO2020252218A1 (en) 2019-06-12 2020-12-17 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
US20220412954A1 (en) 2019-11-05 2022-12-29 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
MX2022006715A (es) 2019-12-06 2022-09-23 Juno Therapeutics Inc Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
BR112022014501A2 (pt) 2020-01-24 2022-09-20 Juno Therapeutics Inc Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva
EP4097218A1 (en) 2020-01-28 2022-12-07 Juno Therapeutics, Inc. Methods for t cell transduction
US20230149462A1 (en) 2020-04-10 2023-05-18 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
CN115812077A (zh) 2020-05-08 2023-03-17 高山免疫科学股份有限公司 April和baff抑制性免疫调节蛋白及其使用方法
US20230178239A1 (en) 2020-05-13 2023-06-08 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CN117321200A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 评估病毒载体颗粒效力的方法
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
BR112023019847A2 (pt) 2021-03-29 2023-11-07 Juno Therapeutics Inc Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
CA3216795A1 (en) 2021-05-07 2022-11-10 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
DE69626681T2 (de) * 1995-11-28 2004-02-12 The Johns Hopkins University School Of Medicine Konditionell-replizierende virale vektoren und ihre verwendung.
WO2001030965A2 (en) 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
US6673567B2 (en) 2000-03-23 2004-01-06 E. I. Du Pont De Nemours And Company Method of determination of gene function
WO2002042482A2 (en) * 2000-11-27 2002-05-30 Chiron Corporation Functional lentiviral vector from an mlv-based backbone
AU2003260769A1 (en) * 2002-09-03 2004-03-29 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
US7220578B2 (en) * 2002-11-27 2007-05-22 Tal Kafri Single LTR lentivirus vector
WO2005023313A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv humans
GB0325379D0 (en) 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
US20060019393A1 (en) * 2003-12-04 2006-01-26 Cannon Paula M Minimal lentiviral vector system
JP2007054069A (ja) * 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom

Also Published As

Publication number Publication date
EP2222861A4 (en) 2011-12-28
TR201802323T4 (tr) 2018-03-21
WO2009076524A2 (en) 2009-06-18
HUE036103T2 (hu) 2018-06-28
PT2222861T (pt) 2018-02-16
US20100323403A1 (en) 2010-12-23
JP2015119715A (ja) 2015-07-02
EP2222861A2 (en) 2010-09-01
PL2222861T3 (pl) 2018-04-30
US10017785B2 (en) 2018-07-10
ES2664988T3 (es) 2018-04-24
EP3342872A1 (en) 2018-07-04
WO2009076524A3 (en) 2009-09-11
JP2011505835A (ja) 2011-03-03
LT2222861T (lt) 2018-03-26
JP5749014B2 (ja) 2015-07-15
RS56844B1 (sr) 2018-04-30
CY1119905T1 (el) 2018-06-27
SI2222861T1 (en) 2018-04-30
DK2222861T3 (en) 2018-02-05
US9796987B2 (en) 2017-10-24
EP2222861B1 (en) 2017-12-06
US20180119170A1 (en) 2018-05-03
JP6001702B2 (ja) 2016-10-05
HRP20180184T1 (hr) 2018-04-06

Similar Documents

Publication Publication Date Title
NO2222861T3 (sr)
BRPI0818930A2 (sr)
CN300729518S (zh) 麻将包装盒(ⅱ)
CN300731431S (zh) 椅(4)
CN301117356S (zh) 后视镜
CN300726134S (zh) 花边(s089622)
CN300726247S (zh) 壁纸(9)
CN300726285S (zh) 玻璃板(波卡圆)
CN300894182S (zh) 玩具(睡狗四)
CN300727176S (zh) 包装袋(jmy-005)
CN300727294S (zh) 工艺品(福字屏风)
CN300727524S (zh) 电连接器
CN300728017S (zh) 标识牌(2)
CN300890524S (zh) 装饰面(2)
CN300875922S (zh) 园林地钻手把
CN300871100S (zh) 笔(视窗)
CN300838343S (zh) 汽车座椅
CN300729957S (zh) 无触点控制装置
CN300820352S (zh) 布(玫瑰圣经)
CN300785757S (zh) Led灯
CN300775002S (zh) 包装盒(初元)
CN300731681S (zh) 纯银保健杯(龙行天下)
CN300731448S (zh) 床架
CN300729779S (zh) 汽车
CN300731301S (zh) 面料(zj-xmas04)